Differential regulation of nicotinic receptor-mediated neurotransmitter release following chronic (-)-nicotine administration

Neuropharmacology

Volumn 43, Issue 5, 2002, Pages 847-856

  Jacobs, Iris ^a   Anderson, David J ^a   Surowy, Carol S ^a   Puttfarcken, Pamela S ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Chronic nicotine treatment; Cortex; Dopamine release; Hippocampus; Nicotinic acetylcholine receptor; Norepinephrine release; Striatum

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CYTISINE; DOPAMINE; EPIBATIDINE; NICOTINE TARTRATE; NICOTINIC RECEPTOR; NORADRENALIN; RECEPTOR SUBTYPE; TRITIUM;

ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; FRONTAL CORTEX; HIPPOCAMPUS; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; REGULATORY MECHANISM;

ALKALOIDS; ANIMALS; AZOCINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CEREBRAL CORTEX; DOPAMINE; HIPPOCAMPUS; MALE; MEMBRANES; NEOSTRIATUM; NEUROTRANSMITTER AGENTS; NICOTINE; NICOTINIC AGONISTS; NOREPINEPHRINE; POTASSIUM CHLORIDE; PYRIDINES; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 0036801724     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00166-1     Document Type: Article

References (55)

1. 3H]-NE from rat brain slices using a new 96-well format assay. Neuropharmacology. 39:2000;2663-2672.
2. Benwell M.E., Balfour D.J. Regional variation in the effects of (-)-nicotine on catecholamine overflow in rat brain. European Journal of Pharmacology. 325:1997;13-20.
3. Buisson B., Vallejo Y.F., Green W.N., Bertrand D. The unusual nature of epibatidine responses at the α4β2 nicotinic acetylcholine receptor. Neuropharmacology. 39:2000;2561-2569.
4. Buisson B., Bertrand D. Chronic exposure to nicotine upregulates the human α4β2 nicotinic acetylcholine receptor function. Journal of Neuroscience. 21:(6):2001;1819-1829.
5. Champtiaux N., Han Z.Y., Bessis A., Rossi F.M., Zoli M., Marubio L., McIntosh J.M., Changeux J.P. Distribution and pharmacology of α6-containing nicotinic acetylcholine receptors analyzed with mutant mice. Journal of Neuroscience. 22:(4):2002;1208-1217.
6. 3H]-dopamine release. British Journal of Pharmacology. 117:1996;595-606.
7. Damsma G., Day J., Fibiger H.C. Lack of tolerance to (-)-nicotine-induced dopamine release in the nucleus accumbens. European Journal of Pharmacology. 168:(3):1989;363-368.
8. El-Bizri H., Clarke P.B.S. Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists adminstered in vitro. British Journal of Pharmacology. 111:1994;606-613.
9. Fenster C.P., Rains M.F., Noerager B., Quick M.W., Lester R.A. Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of (-)-nicotine. Journal of Neuroscience. 17:(15):1997;5747-5759.
10. Fenster C.P., Beckman M.L., Parker J.C., Sheffield E.B., Whitworth T.L., Quick M.W., Lester R.A. Regulation of alpha4beta2 nicotinic receptor desensitization by calcium and protein kinase C. Molecular Pharmacology. 55:1999;432-443.
11. Fenster C.P., Whitworth T.L., Sheffield E.B., Quick M.W., Lester R.A. Upregulation of surface α4β2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to (-)-nicotine. Journal of Neuroscience. 19:1999;4804-4814.
12. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic (-)-nicotine treatment. Molecular Pharmacology. 41:1992;31-37.
13. Flores C.M., Davila-Garcia M.I., Ulrich Y.M., Kellar K.J. Differential regulation of neuronal nicotinic receptor binding sites following chronic (-)-nicotine administration. Journal of Neurochemistry. 69:(5):1997;2216-2219.
14. Giros B., Mestikawy S.E., Godinot N., Zheng K., Han H., Yang-Feng T., Caron M.G. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molecular Pharmacology. 42:1992;383-390.
15. Gopalakrishnan M., Monteggia L.M., Anderson D.J., Molinari E.J., Piattoni-Kaplan M., Donnelly-Roberts D., Arneric S.P., Sullivan J.P. Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor. Journal of Pharmacology and Experimental Therapeutics. 276:(1):1996;289-297.
16. 3H]dopamine release from synaptosomes prepared from mouse striatum. Journal of Neurochemistry. 59:1992;848-856.
17. 3H]-dopamine release from mouse striatal synaptosomes. Journal of Neurochemistry. 62:1994;1390-1398.
18. Grady S.R., Murphy K.L., Cao J., Marks M.J., McIntosh J.M., Collins A.C. Characterization of nicotinic agonist-induced [3H]-dopamine release from synaptosomes prepared from four mouse brain regions. Journal of Pharmacology and Experimental Therapeutics. 301:2002;651-660.
19. Hsu Y.N., Amin J., Weiss D.S., Wecker L. Sustained (-)-nicotine exposure differentially affects alpha 3 beta 2 and alpha 4 beta 2 neuronal nicotinic receptors expressed in Xenopus oocytes. Journal of Neurochemistry. 66:(2):1996;667-675.
20. 3H]dopamine release from rat striatal synaptosomes and slices. Journal of Neurochemistry. 70:1998;1069-1076.
21. Ke L., Eisenhour C.M., Bencherif M., Lukas R.J. Effects of chronic (-)-nicotine treatment on expression of diverse nicotinic acetylcholine receptor subtypes. I. Dose- and time-dependent effects of (-)-nicotine treatment. Journal of Pharmacology and Experimental Therapeutics. 286:1998;825-850.
22. Kulak J.M., Nguyen T.A., Olivera B.M., McIntosh J.M. Alpha-conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. Journal of Neuroscience. 17:1997;5263-5270.
23. 3H]-methylcarbamylcholine binding sites in the rat brain. Journal of Neurochemistry. 52:1989;483-491.
24. Luo S., Kulak J.M., Cartier G.E., Jacobsen R.B., Yoshikami D., Olivera B.M., McIntosh J.M. Alpha-conotoxin AuIB selectively blocks alpha2beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release. Journal of Neuroscience. 18:1998;8571-8579.
25. Lukas R.J. Effects of chronic nicotinic ligand exposure on functional activity of nicotinic acetylcholine receptors expressed by cells of the PC12 rat pheochromocytoma or the TE671/RD human clonal line. Journal of Neurochemistry. 56:(4):1991;1134-1145.
26. Lukas R.J., Ke L., Bencherif M., Eisenhour C.M. Regulation by (-)-nicotine of its own receptors. Drug Development Research. 38:1996;136-148.
27. Marks M.J., Stitzel J.A., Collins A.C. Time course study of the effects of chronic (-)-nicotine infusion on drug response and brain receptors. Journal of Pharmacology and Experimental Therapeutics. 235:1985;619-628.
28. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans-Borgmeyer I., Heinemann S.F., Collins A.C. (-)-Nicotine binding and nicotinic receptor subunit RNA after chronic (-)-nicotine treatment. Journal of Neuroscience. 12:(7):1992;2765-2784.
29. Marks M.J., Grady S.R., Collins A.C. Downregulation of nicotinic receptor function after chronic (-)-nicotine infusion. Journal of Pharmacology and Experimental Therapeutics. 266:(3):1993;1268-1276.
30. Marks M.J., Smith K.W., Collins A.C. Differential agonist inhibition identifies multiple epibatidine binding sites in mouse brain. Journal of Pharmacology and Experimental Therapeutics. 285:1998;377-386.
31. Molinari E.J., Delbono O., Messi M.L., Renganathan M., Arneric S.P., Sullivan J.P., Gopalakrishnan M. Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands. European Journal of Pharmacology. 347:(1):1998;131-139.
32. Moron J.A., Brockington A., Wise R.A., Rocha B.A., Hope B.T. Dopamine uptake with low levels of the dopamine transporter: Evidence from knock-out mouse lines. Journal of Neuroscience. 22:(2):2002;389-395.
33. Nordberg A., Romanelli L., Sundwall A., Bianchi C., Beani L. Effect of acute and subchronic (-)-nicotine treatment on cortical acetylcholine release and on nicotinic receptors in rats and guinea-pigs. British Journal of Pharmacology. 98:(1):1989;71-78.
34. 3H]cytisine binding to nicotinic cholinergic receptors in brain. Molecular Pharmacology. 39:(1):1991;9-12.
35. Paradiso K., Brehm P. Long-term desensitization of nicotinic acetylcholine receptors is regulated via protein kinase A-mediated phosphorylation. Journal of Neuroscience. 18:1998;9227-9237.
36. Pauly J.R., Marks M.J., Gross S.D., Collins A.C. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic (-)-nicotine treatment. Journal of Pharmacology and Experimental Therapeutics. 258:1991;1127-1136.
37. Peng X., Gerzanich V., Anand R., Whiting P.J., Lindstrom J. (-)-nicotine-induced increase in neuronal receptors results from a decrease in the rate of receptor turnover. Molecular Pharmacology. 46:1994;523-530.
38. Povlock S.L., Amara S.G. The structure and function of norepinephrine, dopamine, and serotonin transporters. Reith M.E., Neurotransmitter Transporters. 1997;1-28 Humana Press, New Jersey.
39. 3H]-dopamine release from rat cortex and striatum. Neuropharmacology. 39:2000;2673-2680.
40. Reitstetter R., Lukas R.J., Gruener R. Dependence of nicotinic acetylcholine recovery from desensitization on the duration of agonist exposure. Journal of Pharmacology and Experimental Therapeutics. 289:1999;656-660.
41. Rogers S.W., Gahring L.C., Collins A.C., Marks M. Age-related changes in neuronal nicotinic acetylcholine receptor subunit a4 expression are modified by long-term nicotine administration. Journal of Neuroscience. 18:(13):1998;4825-4832.
42. Rowell P.P., Duggan D.S. Long-lasting inactivation of nicotinic receptor function in vitro by treatment with high concentrations of (-)-nicotine. Neuropharmacology. 37:1998;103-111.
43. Rowell P.P., Wonnacott S. Evidence for functional activity of up-regulated (-)-nicotine binding sites in rat striatal synaptosomes. Journal of Neurochemistry. 55:(6):1990;2105-2110.
44. Sanderson E.M., Drasdo A.L., McCrea K., Wonnacott S. Up-regulation of nicotinic receptors following continuous infusion of (-)-nicotine is brain-region specific. Brain Research. 617:1993;349-352.
45. 3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. Journal of Neurochemistry. 45:1985;427-433.
46. Sershen H., Balla A., Lajtha A., Vizi E.S. Characterization of nicotinic receptors involved in the release of noradrenaline from hippocampus. Neuroscience. 77:1997;121-130.
47. Sharples C.G., Kaiser S., Soliakov L., Marks M.J., Collins A.C., Washburn M., Wright E., Spencer J.A., Gallagher T., Whiteaker P., Wonnacott S. UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2 subtype in the modulation of dopamine release from rat striatal synaptosomes. Journal of Neuroscience. 20:(8):2000;2783-2791.
48. 3H]-epibatidine binding sites. Neuropharmacology. 36:(8):1997;1119-1125.
49. Vizi E.S., Lendvai B. Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in the central nervous system. Brain Research Reviews. 30:1999;287-295.
50. Whiteaker P., Sharples C.G.V., Wonnacott S. Agonist-induced up-regulation of alpha4beta2 nicotinic acetylcholine receptors in M10 cells: pharmacological and spatial definition. Molecular Pharmacology. 53:(5):1998;950-962.
51. 125-I-α-Conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Molecular Pharmacology. 57:2000;91-925.
52. Wonnacott S. Brain (-)-nicotine binding sites. Veterinary and Human Toxicology. 6:1987;343-353.
53. Yamamoto B.K., Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. Journal of Neurochemistry. 71:1998;274-280.
54. Yu Z.J., Wecker L. Chronic (-)-nicotine administration differentially affects neurotransmitter release from rat striatal slices. Journal of Neurochemistry. 63:1994;186-194.
55. Zwart R., Vijverberg H.P. Four pharmacologically distinct subtypes of α4β2 nicotinic acetylcholine receptors expressed in Xenopus laevis ooctyes. Molecular Pharmacology. 54:1998;1124-1131.